logo
logo
ADCT stock ticker logo

ADC Therapeutics SA

NYSE•ADCT
CEO: Dr. Ameet Mallik M.B.A., M.S.
板块: Healthcare
行业: Biotechnology
上市日期: 2020-05-18
ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
联系方式
BiopOle, Route de la Corniche 3B, Epalinges, 1066, Switzerland
41-21-653-02-00
www.adctherapeutics.com
市值
$519.05M
市盈率 (TTM)
-3.4
4.5
股息率
--
52周最高
$4.80
52周最低
$1.05
52周范围
84%
排名61Top 91.5%
2.0
F-Score
改良版 Piotroski 分析
基于 8 年期基本面
疲弱 • 2 / 9 分
评分区间 (0-9)
8-9: 价值优异
6-7: 基本面强劲
4-5: 整体稳健
0-3: 表现疲弱
数据范围: 2018-2025

财务仪表盘

Q3 2025 数据

营业收入

$16.43M-11.03%
近4季度走势

每股收益

-$0.30-28.57%
近4季度走势

自由现金流

-$29.63M+17.30%
近4季度走势

2025 Q3 财报亮点

核心亮点

Revenue Growth Strong Nine months total revenue reached $58.30M, showing 8.1% growth, significantly boosted by $6.03M license revenue increase.
Net Loss Widens Nine months net loss totaled $(136.21M), worsening by 7.2% primarily due to $13.47M in restructuring and impairment charges.
Strong Cash Position Cash and equivalents totaled $234.74M as of September 30, 2025, supporting operations for at least twelve months.
Financing Secured June 2025 Private Placement provided $93.1M net proceeds, supplemented by October 2025 placement proceeds post-period.

关注风险

Restructuring Asset Impairment Recognized $13.47M restructuring costs, including $7.24M impairment loss on long-lived assets related to UK facility closure.
Continued Capital Needs Expectation to continue incurring substantial net losses, necessitating raising additional capital under uncertain market conditions.
Trade Policy Uncertainty Potential US tariffs could increase cost of sales and operating expenses, adversely affecting financial condition.
Drug Pricing Policy Risk New US administration drug pricing policies, like MFN, could substantially reduce ZYNLONTA list price revenues.

前瞻展望

LOTIS-5 Data Timeline Expect topline progression-free survival data from LOTIS-5 confirmatory Phase 3 trial in the first half of 2026.
PSMA ADC Advancement Continue IND-enabling activities for next-generation PSMA-targeting ADC asset, expecting wind-down of related costs by end of 2025.
Future Financing Strategy Plan to fund operating needs through existing cash, ZYNLONTA revenue, and exploring strategic collaborations or debt financings.
LOTIS-7 Data Update Plan to share more mature LOTIS-7 trial data via corporate update by year-end, followed by FDA engagement.

同行对比

营业收入 (TTM)

ADCT stock ticker logoADCT
$75.21M
+6.4%
LXRX stock ticker logoLXRX
$70.86M
+1255.2%
AUTL stock ticker logoAUTL
$51.13M
+406.7%

毛利率 (最新季度)

ALMS stock ticker logoALMS
100.0%
+0.0pp
BCYC stock ticker logoBCYC
100.0%
+1705.8pp
LCTX stock ticker logoLCTX
98.9%
+0.9pp

关键指标

股票代码
市值
市盈率 (TTM)
净资产收益率 (TTM)
负债率
ALMS$2.89B-11.7-75.5%7.7%
RAPT$959.51M-14.8-61.8%1.6%
OMER$814.65M-6.357.3%103.2%

长期趋势

近4季度
营业收入
净利润
经营现金流
4季度营收复合增长率
-1.0%
基本持平
4季度净利润复合增长率
N/M
盈利状态转变
现金流稳定性
0%
现金流需要关注

深度研究

下次财报:2026年3月10日
|
每股收益:-$0.32
|
营业收入:$22.29M
财务数据
电话会议
财务报告
新闻
利润表
资产负债表
现金流量表
财务比率
变化率
利润表
过去12个月
无数据